Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor alpha 1
- Author(s)
- Redpath, NT; Xu, YB; Wilson, NJ; Fabri, LJ; Baca, M; Andrews, AE; Braley, H; Lu, P; Ireland, C; Ernst, RE; Woods, A; Forrest, G; An, ZQ; Zaller, DM; Strohl, WR; Luo, CS; Czabotar, PE; Garrett, TPJ; Hilton, DJ; Nash, AD; Zhang, JG; Nicola, NA;
- Journal Title
- BIOCHEMICAL JOURNAL
- Publication Type
- Journal Article
- Abstract
- Gene deletion studies in mice have revealed critical roles for IL (interleukin)-4 and -13 in asthma development, with the latter controlling lung airways resistance and mucus secretion. We have now developed human neutralizing monoclonal antibodies against human IL-13R alpha 1 (IL-13 receptor al) subunit that prevent activation of the receptor complex by both IL-4 and IL-13. We describe the crystal structures of the Fab fragment of antibody 10G5H6 alone and in complex with D3 (ectodomain 3) of IL-13R alpha 1. Although the structure showed significant domain swapping within a D3 dimer, we showed that Are(230), Phe(233), Tyr(250), Gln(252) and Leu(293) in each D3 monomer and Ser(32)', Asn(102) and Tre(103) in 10G5H6 Fab are the key interacting residues at the interface of the 10G5H6 Fab-D3 complex. One of the most striking contacts is the insertion of the ligand-contacting residue Leu(293) of D3 into a deep pocket on the surface of 10G5H6 Fab, and this appears to be a central determinant of the high binding affinity and neutralizing activity of the antibody.
- Publisher
- PORTLAND PRESS LTD
- Keywords
- ASTHMA; CLONING; DISEASE; CHAIN; GENE; SELECTION; SYSTEM; SITE
- Research Division(s)
- Cancer And Haematology; Molecular Medicine; Structural Biology
- Publisher's Version
- https://doi.org/10.1042/BJ20121819
- Terms of Use/Rights Notice
- © The Authors Journal compilation © 2013 Biochemical Society
Creation Date: 2013-04-15 12:00:00